Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week Phase 3 randomized double-blind placebo-controlled study of relamorelin in diabetic gastroparesis
2017-002144-33Phase 3Terminated
- Sponsor
- Allergan
- Start
- Jul 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic gastroparesis comparing Relamorelin with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in the weekly DGSSS. Started Jul 2018; status: terminated.
02
Drugs
relamorelin
03
Conditions
diabetic gastroparesis
Beyond the preview
Go deeper on 2017-002144-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002144-33.